Join the conversation at #GIFORUMCCFA
|
|
- Warren Wilson
- 5 years ago
- Views:
Transcription
1 1
2 Join the conversation at #GIFORUMCCFA 2
3 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made: Planning Committee Member John Bayliss, VP, Business Development, Annenberg Center for Health Sciences at Eisenhower Spouse is an employee of Amgen Julie Messick, PharmD No Relevant Relationships Faculty All faculty disclosures can be found in your meeting guide. 3
4 This program is supported by educational grants from Janssen Biotech, Inc. Prometheus Laboratories, Inc. 4
5 5
6 Case Presentation 6
7 Patient Case 23-yr-old male presents with 8 weeks of progressive abdominal pain and weight loss Physical exam BMI 22 T Pulse 105 Tender with fullness in RLQ 7
8 Patient Case (cont.) No family history of IBD Smokes 1 ppd Labs WBC 10, Hgb 10, Hct 34 Ferritin 30 CRP 15 mg/dl CMP normal except albumin 3.1 g/l Vitamin B 12 normal, Vitamin D low 8
9 Patient Case (cont.) MRE: edematous ileum with mesenteric stranding and sinus tract toward sigmoid colon Colonoscopy: Focal area of ulceration in sigmoid. Deep ulcerations in cecum with deformed and ulcerated ileocecal valve 9
10 Personalizing Treatment for IBD: Evolving Treatment Paradigms Maria T. Abreu, MD 10
11 Impact of Therapy Will Depend on Degree of Structural Damage and Speed of Progression 100 Cumulative probability, % Inflammatory Penetrating Stricturing Patients at risk Months n= Cosnes J et al. Inflamm Bowel Dis. 2002;8:
12 AGA Clinical Pathway for Crohn s Disease: Assessing Inflammatory Status Assess inflammatory status Assess symptoms/signs Fever Abdominal pain GI bleeding Localized tenderness Weight loss Joint pain Cutaneous signs Perform clinical lab testing CBC CRP CMP Fecal calprotectin ESR Select imaging modalities (if indicated) Identify symptoms without inflammatory markers Perform endoscopy Identify symptoms with inflammatory markers* Perform CTE or MRE Consider whether treatment decisions to be based on inflammatory markers vs confirming with colonoscopy. This may depend on whether there was historically good correlation between the biomarker selected and colonoscpy in the specific patient. CMP, complete metabolic panel; CTE, computed tomography enterography; ESR, erythrocyte sedimentation rate; MRE, magnetic resonance enterography. Sandborn WJ. Gastroenterology. 2014;147:
13 AGA Clinical Pathway for Crohn s Disease: Characterizing Risk Low Risk High Risk >30 years Age at diagnosis <30 years Limited Anatomic involvement Extensive No Perianal and/or severe rectal disease Yes Superficial Ulcers Deep No Prior surgical resection Yes No Stricturing and/or penetrating behavior Yes Sandborn WJ. Gastroenterology. 2014;147:
14 AGA Clinical Pathway for Crohn s Disease: Initial Treatment Low-risk patient Moderate/high-risk patient Ileum and/or proximal colon, none to minimal symptoms Options Budesonide 9 mg/day with or without AZA Tapering course of prednisone with or without AZA Diffuse or left colon, none to minimal symptoms Options Tapering course of prednisone with or without AZA Options Anti-TNF monotherapy over no therapy or thiopurine monotherapy Anti-TNF + thiopurine over thiopurine monotherapy or anti-tnf monotherapy Methotrexate for patients who do not tolerate purine analog in combination with anti-tnf Sandborn WJ. Gastroenterology. 2014;147:
15 Clinical Remission in CD: Net Remission at 6 Months with TNF Antagonists 1. Hanauer SB et al. Lancet. 2002;359: ; 2. Colombel JF et al. Gastroenterology. 2007;132:52-62; 3. Schreiber S et al. N Engl J Med. 2007;357: ; 4. Sandborn WJ et al. N Engl J Med. 2007;357:
16 Improving Initial Response to Biologics Treat earlier in course (before complications) Ensure Complete response Combination therapy 16
17 Early Aggressive Biologic Therapy versus Conventional Management of Crohn s Disease Newly-diagnosed Crohn s disease (N=133)* No previous anti-tnf, antimetabolite, or steroids + IFX IFX + AZA + AZA/MTX + (episodic) IFX Steroids Steroids Steroids Conventional Therapy (n=66) Early Aggressive (n=67) *Within 4 years. D Haens G et al. Lancet. 2008;371(9613):
18 Complete Ulcer Disappearance Mucosal Healing at Week 104 Patients with no ulcers, % n=19/26 Top-down therapy P= n=7/23 Step-up therapy D Haens G et al. Lancet. 2008;371(9613):
19 CHARM: Early CD Shows High Levels of Remission with Adalimumab Patients in remission, % Week 26 P=0.002 P< < 2 years 2 to 5 years 5 years Disease duration Clinical Remission Patients in remission, % Placebo All adalimumab 0 P= Week 56 P=0.001 P= n=23 n=39 n=23 n=39 n=111 n=233 n=23 n=39 n=23 n=39 n=111 n=233 < 2 years 2 to 5 years 5 years Disease duration Schreiber S, et al. Gastroenterology. 2007;132(Suppl 1):A
20 Response and Remission to Certolizumab Pegol in Crohn s Disease vs. Disease Duration CDAI response, % Clinical Response n=35 n=19 n=22 n=20 n=55 n=45 n=98 n=131 < 1 year 1 to 2 years 2-5 years 5 years Disease duration Placebo PRECiSE Trial Sandborn WJ, et al. Am J Gastroenterol. 2006;101:S [Abstract 1109]. Schreiber S, et al. N Engl J Med. 2007;357(3): CDAI remission % Certolizumab pegol Clinical Remission < 1 year 1 to 2 years 2-5 years 5 years Disease duration n=35 n=19 n=22 n=20 n=55 n=45 n=98 n=131 20
21 Combination Therapy in CD: The SONIC Study Patients (%) Corticosteroid-free Clinical Remission at Week P= P<.001 P= /170 75/169 96/169 Azathioprine Infliximab Azathioprine + Infliximab Combination therapy with immunosuppressant and anti-tnf biologic offers improved efficacy and durability compared with anti-tnf monotherapy 2 1. Colombel JF et al. N Engl J Med. 2010;362: Sandborn WJ. Gastroenterology. 2014;147:
22 Mucosal healing improves outcomes 22
23 Mucosal Healing After Therapy Predicts Improved Outcomes in Crohn s Disease 100 SES 0 SES 1 8 Patients (%) Remission off steroids Remission off steroids and anti-tnf SES=Simple Endoscopic Score. Baert F et al. Gastroenterology. 2010;138:
24 Mucosal Healing Reduces Risk for Colectomy in Crohn s Disease Risk of Colectomy According to Severe Endoscopic Lesions 1 Degree of Mucosal Healing and Risk of Major Abdominal Surgery 2 Patients (%) No severe endoscopic lesions Severe endoscopic lesions Patients undergoing MAS (%) Year of follow-up 0 Complete Partial None Degree of mucosal healing MAS=major abdominal surgery; SEL=severe endoscopic lesions (extensive and deep ulcerations on index colonoscopy) 1. Allez M et al. Am J Gastroenterol. 2002;97: Schnitzler F et al. Inflamm Bowel Dis. 2009;15:
25 Biomarkers Correlate Well With Endoscopic But Not Clinical Activity Indices IL-6 Calprotectin Lactoferrin CDAI SES-CD hscrp NS + IL NS + Calprotectin Lactoferrin + + CDAI NS + indicates significant correlation coefficients (P<.05); NS, nonsignicant correlations. When stratified by extent, correlation coefficients were highest for colonic disease CDAI=Crohn s disease activity index; CRP=C-reactive protein; IL=interleukin; SES-CD=Simple Endoscopic Score-Crohn s Disease. Jones JL et al. Clin Gastroenterol Hepatol. 2008;6:
26 Working Definitions of Deep Remission Deep remission implies resolution of inflammatory symptoms and objective signs of inflammation No bowel damage or disability Resolution of symptoms Resolution of objective measures of inflammation (endoscopy, imaging, biomarkers) Existing bowel damage or disability Improvement of symptoms Resolution of objective measures of inflammation (endoscopy, imaging, biomarkers) Colombel JF et al. Dig Dis. 2012;30 Suppl 3:
27 Not All Decisions in Crohn s Disease Are Preference-Sensitive Preference-Sensitive Decisions Anti-TNF monotherapy vs anti-tnf plus thiopurine therapy Top-down versus rapid step-up therapy at diagnosis Infliximab vs adalimumab vs certolizumab Ileocolonic resection vs augmenting therapy for persistent non-stricturing CD Anti-integrin vs 2 nd or 3 rd anti-tnf Non-Preference-Sensitive Decisions TB testing prior to initiating anti-tnf therapy Appropriate vaccinations for immunosuppressed patients Siegel CA. Gut. 2012;61:
28 Helping Patients See The Odds Risk of Lymphoma Associated with Immune Suppression (9 per 10,000 patient-years) Risk of Serious Infections in the SONIC Trial Siegel CA. Aliment Pharmacol Ther. 2011;33:
29 Patient Case (cont.) He is started on combination adalimumab and azathioprine but develops nausea and vomiting 3 weeks after starting azathioprine He improves after stopping azathioprine After 12 weeks of therapy he begins to develop recurrence of abdominal pain and night sweats CRP is 8 g/l 29
30 Managing Loss of Response to Anti-TNF Therapies Edward V. Loftus, Jr., MD 30
31 How to Maintain Remissions with Biologics Prospective Therapeutic Monitoring 31
32 Therapeutic Windows with Biologics Peak Concentration (µg/ml) Trough Time (weeks) 32
33 Implications of Low Trough Levels Disease recurs No longer maintenance but re-treatment Development of anti-drug antibodies Eventual loss of response 33
34 What Factors Influence the Pharmacokinetics of TNF Antagonists? Y Decreases drug clearance Concomitant immunosuppressives CRP=C-reactive protein Ordàs I et al Clin Gastroenterol Hepatol. 2012;10: Increases drug clearance Anti-drug antibodies Low serum albumin High baseline CRP High baseline TNF concentration High body mass index Male sex 34
35 Detectable Levels of Infliximab Are Associated with Better Outcomes Patients (%) Clinical Outcomes By Infliximab Trough Level 6 P< Undetectable P< µg/ml P<0.001 Clinical remission Normal CRP Endoscopic improvement 88 Maser EA et al. Clin Gastroenterol Hepatol. 2006;4:
36 Clinical Remission Without Corticosteroids by Trough IFX Concentration at Week 26: SONIC Patients (%) Corticosteroid-free Remission at Week /32 13/23 43/59 36/49 31/43 0 >0-1 >1-3 >3-6 >6 IFX concentration (µg/ml) at Week 30 Colombel JF, et al. N Engl J Med
37 Post-induction Infliximab Levels Predict Clinical Outcome at Week 54 Patients, % P= Week 14 serum IFX level <3.5 µg/ml 3.5 µg/ml Sustained response (n=96) No sustained response (n=51) Cornillie F et al., Gut. 2014;63:
38 Infliximab Trough Between Weeks 14 and 22 Predicts Sustained Response in Crohn s Disease Retrospective adult cohort 84 patients IFX trough level measured at 14 or 22 weeks Sustained clinical response IFX Trough level > 3 µg/ml Increase in ATI IFX Trough level < 3 µg/ml Bortlik M, et al. J Crohns Colitis. 2013;7: Cumulative probability of sustaining in clinical response P-value (logrank): <0.001 IFX level >3 µg/ml <3 µg/ml Time from IFX start (months) 38
39 Active Monitoring of Anti-TNF Levels May Ensure Durability of Response Prospectively optimized IFX trough concentrations to a target range of 5-10 µg/ml 100 Probability on Infliximab Vaughn B, et al. Inflamm Bowel Dis. 2014;20: P= Weeks Optimized Not Optimized 39
40 Assessing Loss of Response Reassess disease activity Measure drug level and anti-drug antibodies If possible? 40
41 Assessing Loss of Response Confirmed Active Inflammation Subtherapeutic concentration and positive ADA Therapeutic drug concentration or detectable trough level Subtherapeutic concentration or undetectable trough level Change to another anti-tnf agent Increase dose frequency If persistent disease Change to treatment with different MOA (non-anti-tnf agent) or Consider adding immunosuppressant (if monotherapy) ADA, anti-drug antibodies. Afif W et al. Am J Gastroenterol. 2010;105:
42 Increasing Dose of Infliximab in the Presence of ATI Formation is Inferior to Changing Anti-TNF Complete/partial response, % Patients with detectable ATI (n=35) 92 P<0.004 Complete/Partial Response n=11/12 n=1/6 0 n=11/12 n=1/6 Anti-TNF changed Complete/partial response, % Patients with sub-therapeutic IFX concentrations (n=69) 33 P<0.016 Infliximab increased 86 Afif W et al. Am J Gastroenterol. 2010;105:
43 Adalimumab & ATA Levels at LOR Correlate With Response to Dose Intensification Adalimumab Levels at the Time of LOR in Patients Who Subsequently Responded to Dose Intensification Compared with Those Who Did Not ATA Levels at the Time of LOR in Patients Who Subsequently Responded to Dose Intensification Compared with Those Who Did Not mcg/ml mcg/ml-eq LOR, loss of response. Yanai et al. Clin Gastroenterol Hepatol. 2015;13:
44 Patient Case Adalimumab trough level is undetectable Anti-drug antibodies are positive What would you do next? 44
45 The First Biologic is the Best Opportunity Longer disease duration Progressive transmural changes Refractory disease 45
46 4-Week Remission Rate with Adalimumab By Prior Anti-TNF Exposure Patients in remission, % Clinical Remission (CDAI 150) at Week 4 Placebo Adalimumab 160 mg (Wk 0)/80 mg(wk 2) 12 P< Anti-TNF-naïve (CLASSIC-I) 7 P< n=74 n=76 n=166 n=159 Infliximab failure/intolerance (GAIN) Adapted from Accessed 0708/09. Sandborn WJ, et al. Ann Intern Med. 2007;146(12):
47 Certolizumab Pegol: Week 26 Clinical Remission by Prior Anti-TNF Exposure Patients in remission, % Clinical Remission (CDAI 150) in PRECiSE 2 Certolizumab pegol (3 injections) + placebo Certolizumab pegol 400 mg 33.3 P< No prior anti-tnf 13.7 P= n=159 n=163 n=51 n=52 Prior anti-tnf (infliximab) Schreiber S, et al. N Engl J Med. 2007;357(3): Columbel JF, et al. Presented at UEGW 47
48 Vedolizumab in Crohn s Disease: Clinical Remission at Week 6 and Clinical Remission at Week Clinical Remission at Week 10 Patients, % P= Patients, % P=.001 P< Overall population Failure Naïve TNF antagonist experience 0 Overall population Failure Naïve TNF antagonist experience Placebo Vedolizumab Q8W PBO=placebo; VDZ=vedolizumab Sands BE et al. Gastroenterology. 2014;147:
49 Effect of Concomitant Azathioprine or Methotrexate on Anti-drug Antibodies ATI IFX levels Patient 1 Patient 3 Concentration (mcg/ml) Start MTX Concentration (mcg/ml) Start AZA Weeks Weeks Ben-Horin S, et al. Clin Gastroenterol Hepatol. 2013; 11:
50 Patient Case He was treated with infliximab 5mg/kg induction and maintenance and methotrexate 15 mg orally He did well for 6 months but then had recurrence of pain, fever and diarrhea Colonoscopy demonstrated a fistula in the sigmoid and persistent deep ulcers in the cecum and a strictured ileocecal valve. Infliximab levels were 9 and there were no anti-drug antibodies What would you do next? 50
51 The IBD Pipeline IL-Inhibitors Ustekinumab Multiple anti-il-23 inhibitors Downstream signaling blockade Tofacitinib Ozanimod Mongersen Anti-adhesion molecules Alicaforsen AMG181 Anti-MAdCAM Etrolizumab Adapted from Amiot A, Peyrin-Biroulet L. Ther Adv Gastroenterol. 2015;8(2):66-82.c 51
52 Ustekinumab for Crohn s Disease p40 IL-12 p35 ustekinumab NK or T cell membrane No IL-12 or IL-23 Intracellular signal p19 IL-23 p40 IL-12 and IL-23 are key cytokines in the pathogenic immune cascade of CD Ustekinumab is a fully human IgG1k monoclonal antibody that binds the p40 subunit of Interleukins-12 & 23 Prevents IL-12 and IL-23 from binding IL-12Rβ1 Inhibits IL-12 and IL-23 mediated signaling, cellular activation, and cytokine production Approved for moderate to severe psoriasis and psoriatic arthritis Feagan B, et al. UEGW
53 UNITI-2 Trial Ustekinumab in Anti-TNF-Naïve CD Patients Patients, % Clinical Response at Week 6 ( 100 point CDAI reduction) P<0.001 P<0.001 P< n=209 n=209 n=209 n=418 Placebo 130 mg ~6 mg/kg* Combined Ustekinumab *Weight-range based UST doses approximating 6 mg/kg: 260 mg (weight 55 kg), 390 mg (weight >55 mg and 85 kg), 520 mg (weight >85 kg). Subjects who had a prohibited Crohn's disease-related surgery or had prohibited concomitant medication changes prior to designated analysis time point are considered not to be in clinical response, regardless of their CDAI score. Subjects who had insufficient data to calculate the CDAI score at designated analysis endpoint are considered not to be in clinical response. Feagan BG et al. UEGW
54 UNITI-1 Trial Ustekinumab in CD Patients Failing Anti-TNF Therapy Subjects, % 50 P= p=0.001 *Weight-range based UST doses approximating 6 mg/kg: 260 mg (weight 55 kg), 390 mg (weight >55 mg and 85 kg), 520 mg (weight >85 kg). Subjects who had a prohibited Crohn's disease-related surgery or had prohibited concomitant medication changes prior to designated analysis time point are considered not to be in clinical response, regardless of their CDAI score. Subjects who had insufficient data to calculate the CDAI score at designated analysis endpoint are considered not to be in clinical response. Sandborn WJ, et al. CCFA Clinical Response at Week 6 ( 100 point CDAI reduction) P= n=247 n=245 n=249 Placebo 130 mg ~6 mg/kg* Ustekinumab 54
55 UNITI-2 Ustekinumab General Safety Summary SAEs were uncommon and, except for Crohn s disease, anal abscess, and small bowel obstruction, no individual SAE was reported in >1 subject in any group No deaths, malignancies, or MACE through Week 8 Proportions of subjects with infections similar across all ustekinumab and placebo groups No cases of TB and no opportunistic infections in ustekinumab-treated subjects Adverse events during or within an hour of infusion were infrequent, and did not occur at a higher rate in ustekinumab groups vs. placebo None were serious, and no anaphylaxis events were reported Feagan B et al. UEGW
56 Mongersen (GED-0301): Phase 2 Trial in Steroid-dependent or -resistant CD Clinical Remission at Week 12 P<0.001 P<0.001 Patients, % Placebo (n=42) P< mg/day (n=41) P< mg/day (n=40) mg/day (n=43) Monteleone G et al. N Engl J Med. 2015;372: Mongersen 56
57 Summary Early aggressive treatment according to prognosis vs symptoms Treatment decisions based on objective measures Prevent loss of response Assess loss of response and mechanisms Share decisions with patients 57
58 Panel Discussion 58
Join the conversation at #IBDNEWSDDW
1 Join the conversation at #IBDNEWSDDW 2 Connect to Our Network Connect to the free GiHF network, via Wi-Fi Open GiHF.com To ask a question, get more information, or view slides, click Quick Join at the
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationManaging Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationModern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions
Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions Rami Ismail, Pharm.D., BCPS, BCCCP, CACP Lead Clinical staff Pharmacist, Cleveland Clinic Abu Dhabi Disclosure Information
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More informationOp#mal Therapy in IBD: Where Are We Now?
Op#mal Therapy in IBD: Where Are We Now? Brian G. Feagan MD Professor of Medicine, Epidemiology and Biosta;s;cs Western University Senior Scien;fic Director, Robarts Clinical Trials, London, Ontario, Canada
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationThe evaluation and treatment of patients with Crohn s
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:395 399 PERSPECTIVE Do Not Assume Symptoms Indicate Failure of Anti Tumor Necrosis Factor Therapy in Crohn s Disease DAVID H. BRUINING* and WILLIAM J. SANDBORN
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More information4/16/2018. Updates in Crohn s Disease. Disclosures. Learning Objectives. Crohn s Disease is Progressive and Destructive
4/16/218 Disclosures Updates in Crohn s Disease David T. Rubin, MD Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Consultant
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationIdentifying and Managing Patients with IBD at Risk for Progressive Disease
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Francis A. Farraye, MD, MSc, FACG Professor of Medicine Clinical Director, Section of Gastroenterology Boston University School of Medicine Boston,
More informationPD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten?
PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Fisteln bei M. Crohn : Konservative Behandlungsmöglichkeiten? INTERDISZIPLINÄRE VISZERALE CHIRURGIE
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationAdvances in the development of new biologics in inflammatory bowel disease
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-6 Advances in the development of new biologics in inflammatory bowel disease Bella Ungar, Uri Kopylov Sheba Medical Center, Tel Hashomer and Sackler
More information